Abstract 4556: Preclinical pharmacology and safety of RO7297089, a novel anti-BCMA/CD16a bispecific antibody for the treatment of multiple myeloma
Sign Up to like & getrecommendations! Published in 2020 at "Immunology"
DOI: 10.1158/1538-7445.am2020-4556
Abstract: RO7297089 is a bispecific antibody (IgG-scFv) targeting Bcell maturation antigen (BCMA) and CD16a (FcγRIIIA) that is being developed for the treatment of multiple myeloma (MM). BCMA is exclusively expressed on plasmablasts and differentiated plasma cells… read more here.
Keywords: ro7297089; treatment; bcma; cd16a ... See more keywords